This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The first clinical trial of an Ebola vaccine is expected to begin in the Democratic Republic of Congo by the end of October, World Health Organization experts said Tuesday.

DR Congo's worst-ever Ebola outbreak has passed the 9,000-case mark, with the number of deaths exceeding 4,000.

Among the many challenges facing the response is the lack of any approved vaccines or treatments for the Bundibugyo species of Ebola behind the outbreak.

Ervebo, a vaccine approved for use against the more common Zaire strain of Ebola, will go through a full-scale human trial in the DRC to see if it offers any cross-protection against Bundibugyo.

"We have got strong reassurances that ... it should be starting before the end of this month," said Anthony Scott, chair of the WHO's Strategic Advisory Group of Experts on Immunisation (SAGE).

The group said insights that Ervebo might offer cross-protection against Bundibugyo were no match for evidence from standardized vaccine trials.

The so-called Tumaini trial in the DRC—a single trial framework that can test the efficacy of multiple vaccines—should also eventually incorporate two Bundibugyo-specific candidate vaccines, which are moving through earlier-stage, smaller-scale clinical trials.

One is a ChAdOx1 adenoviral vector shot being developed by the University of Oxford; the other, by the U.S.-based Moderna group, uses mRNA technology.

The Tumaini trial "will generate urgently needed data on the efficacy of Ervebo against Bundibugyo virus disease, and will help formulate the policy decisions we need," Scott told a press conference.

Source link